Ulanet et al. discovered that this high ratio renders BC cells insensitive to IGF1R antibody (A12) treatment, while knockdown of IR significantly enhances the inhibitory effect of A12 on BC cells (Ulanet et al., 2010). The gene discussed is IGF1R; the disease is breast cancer.